Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd (QNRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare dermatological disorders and orphan diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical trial progress, and strategic partnerships central to advancing treatments for conditions like Netherton Syndrome and Epidermolysis Bullosa.
Access authoritative information on Quoin's therapeutic pipeline developments, including FDA designations and international trial expansions. The page consolidates official press releases, research collaborations, and manufacturing updates while maintaining strict compliance with financial disclosure standards.
Key content areas include phase trial results, intellectual property announcements, and partnership agreements with biotechnology innovators. All materials are curated to support informed decision-making without speculative commentary or investment recommendations.
Bookmark this page for streamlined tracking of Quoin's progress in addressing unmet medical needs through targeted drug development programs and evidence-based research initiatives.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported positive interim data from two ongoing Netherton Syndrome clinical studies for its QRX003 treatment. In the first study, a subject receiving twice-daily dosing showed significant improvements after six weeks: Modified Ichthyosis Area of Severity Index (MIASI) reduced from 18 to 4, Investigator's Global Assessment (IGA) improved from 'moderate' to 'mild', and pruritus assessment decreased from 7 to 4 on the Worst Itch Numeric Rating Scale.
In the second study, a pediatric patient showed marked improvement after just 12 days of treatment, with IGA classification improving from 'severe' to 'mild-moderate'. No safety concerns were reported in either study.
Quoin Pharmaceuticals (NASDAQ: QNRX) reported Q3 2024 developments and financial results. The company initiated a clinical study for QRX003 in Peeling Skin Syndrome in New Zealand and expanded its Netherton Syndrome trials with two new UK sites. Financial results showed a net loss of $2.3 million for Q3 2024, compared to $1.9 million in Q3 2023. Cash position stands at $10.3 million, expected to fund operations into late 2025. The management team made significant insider share purchases, demonstrating confidence in the company's trajectory.
Quoin Pharmaceuticals (NASDAQ: QNRX) has begun testing QRX003 in a pediatric patient with Netherton Syndrome (NS) at Children's Health Ireland in Dublin, led by Dr. Alan Irvine. The company plans to expand testing to include three additional pediatric patients in Spain. QRX003 is currently being evaluated in two late-stage clinical trials, with promising results showing improvement across multiple endpoints and no treatment-related adverse events. The company is expanding its clinical sites beyond the existing five U.S. locations, with new sites planned in Saudi Arabia and two in the United Kingdom.
Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced it will release its third quarter 2024 financial results before market opens on Thursday, November 7, 2024. The announcement will include an operational update on company achievements during the quarter and financial highlights.
Quoin Pharmaceuticals (NASDAQ: QNRX) has announced the expansion of its ongoing Netherton Syndrome (NS) clinical trials to include two additional sites in the United Kingdom. The new sites are Great Ormond Street Hospital and St. Thomas' Hospital in London, both recognized as centers of excellence for treating NS patients. A Principal Investigator has been appointed, and a Clinical Research Organization has been engaged for the UK studies.
These sites, along with the previously announced site in Saudi Arabia, will operate under Quoin's open Investigational New Drug (IND) application with the US FDA. The company is also preparing to open additional sites in Western and Eastern European countries with available NS patient cohorts.
Quoin is currently conducting two clinical trials evaluating QRX003, a topical lotion, for the treatment of Netherton Syndrome. The company aims to complete enrollment in both studies rapidly to potentially deliver the first approved treatment for this rare, inherited genetic disease.
Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company, announced significant insider share purchases by its co-founders. CEO Michael Myers acquired 37,894 American Depositary Shares (ADSs) at prices ranging from $0.619 to $0.7974 per ADS on September 3-4, 2024. Similarly, COO Denise Carter purchased 37,735 ADSs between $0.6253 and $0.7965 per ADS during the same period.
These insider purchases are viewed as a strong signal of leadership confidence in Quoin's growth trajectory and commitment to delivering long-term shareholder value. The company focuses on developing and commercializing novel treatments for rare and orphan diseases, aiming to address unmet needs in underserved patient populations globally.
Quoin Pharmaceuticals (NASDAQ: QNRX) has provided a corporate update and announced financial results for Q2 2024. Key highlights include:
1. Research agreement with University College Cork to develop topical rapamycin formulations.
2. Expansion of Netherton Syndrome clinical trials internationally.
3. Plans to initiate a clinical study in Peeling Skin Syndrome.
4. Continued evaluation of M&A opportunities in rare and orphan diseases.
Financial highlights:
- Cash position of $12.6 million as of June 30, 2024.
- Net loss of $2.0 million for Q2 2024, compared to $2.1 million in Q2 2023.
- Net loss of $4.3 million for H1 2024, compared to $4.7 million in H1 2023.
Quoin Pharmaceuticals (NASDAQ: QNRX) has announced plans to initiate a clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome (PSS), a rare autosomal disease with no approved treatment. The study will focus on a pediatric patient, with the company actively exploring additional clinical sites in other countries.
QRX003, Quoin's most advanced pipeline product, is already being tested in two late-stage clinical trials for Netherton Syndrome (NS) in the United States under an FDA-approved IND. The company aims to expand QRX003's development into PSS, leveraging potential similarities in the diseases' mechanisms. This move aligns with Quoin's strategy to broaden QRX003's applications in rare and orphan diseases.
Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company focusing on rare and orphan diseases, has announced plans to release its second quarter 2024 financial results before market opening on Thursday, August 8, 2024. The upcoming announcement will include an operational update highlighting the company's achievements during the quarter, along with financial highlights. This pre-market release will provide investors and analysts with important information about Quoin's performance and progress in its specialized field of rare disease therapeutics.
Quoin Pharmaceuticals (NASDAQ: QNRX) announces the international expansion of its clinical trials for Netherton Syndrome. The first international site will open at a research hospital in Saudi Arabia, which is currently treating eligible Netherton patients. An experienced local Clinical Research Organization will manage the study. The site will operate under Quoin's IND application with the US FDA. Additional international sites are also being planned. CEO Dr. Michael Myers highlighted that this expansion aims to accelerate patient recruitment and diversify the patient population. Quoin is conducting two ongoing trials evaluating QRX003, a topical lotion, for Netherton Syndrome.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
